After years of research, we can now modulate how the microbiota influence lung diseases. The commercialization of this work from University of Alabama at Birmingham, led by ResBiotic founder and Chief Scientific Officer C. Vivek Lal MD FAAP, has the potential to be life changing for respiratory disease patients.In the last 5-10 years, associations between alterations in airway microbiota and airway diseases have been reported ...
After years of research, we can now modulate how the microbiota influence lung diseases. The commercialization of this work from University of Alabama at Birmingham, led by ResBiotic founder and Chief Scientific Officer C. Vivek Lal MD FAAP, has the potential to be life changing for respiratory disease patients.In the last 5-10 years, associations between alterations in airway microbiota and airway diseases have been reported at an increasing rate. Resbiotic founder and Chief Scientific Officer C. Vivek Lal, in his research at UAB, has been a pioneer of this research.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.